Effect of Metformin Versus Repaglinide Treatment in Non-Obese Type 2 Diabetic Patients Uncontrolled by Diet
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
Background: Metformin is the first drug of choice in obese patients with type-2 diabetes
(T2DM) due to its antiglycaemic as well as its cardiovascular protective potentials. In
non-obese T2DM patients insulin-secretagogues are empirically used as first choice. The aim
of this study was to evaluate the effect of metformin versus an insulin-secretagogue,
repaglinide on glycaemic regulation and non-glycaemic cardiovascular risk markers in
non-obese patients with T2DM.
Methods: Single-center, randomised, double-masked, double-dummy, cross-over-study of 96
non-obese (BMI ≤ 27 kg/m2) Caucasian T2DM-patients. After a one month run-in on diet-only
treatment, patients were randomised to either repaglinide 2mg three times a day (t.i.d).
followed by metformin 1g twice a day (b.i.d.) or vice versa each for a period of four months
with a one month wash-out between interventions.
Phase:
Phase 4
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen